{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:52:20Z","timestamp":1791921140739,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-07443-y","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:46:54Z","timestamp":1790693214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous infliximab for maintenance therapy in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-0831","authenticated-orcid":false,"given":"Douglas Amaral da Silva Menegazzo","family":"Miotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Ov\u00eddio","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Molina","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"7443_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","volume":"162","author":"ME Kuenzig","year":"2022","unstructured":"Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC, Wilson DC, Cameron F, Henderson P, Kotze PG, Bhatti J, Fang V, Gerber S, Guay E, Kotteduwa Jayawarden S, Kadota L, Maldonado DF, Osei JA, Sandarage R, Stanton A, Wan M, InsightScope Pediatric IBD Epidemiology Group, Benchimol EI (2022) Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 162:1147\u20131159. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.282","journal-title":"Gastroenterology"},{"key":"7443_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/MPG.0000000000002842","volume":"71","author":"CJ Burgess","year":"2020","unstructured":"Burgess CJ, Henderson P, Jones GR, Lees CW, Wilson DC, Lothian IBD Registry Group (2020) Paediatric patients (less than age of 17 years) account for less than 1.5% of all prevalent inflammatory bowel disease cases. J Pediatr Gastroenterol Nutr 71:521\u2013523. https:\/\/doi.org\/10.1097\/MPG.0000000000002842","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7443_CR3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i35.111934","volume":"31","author":"M Al-Beltagi","year":"2025","unstructured":"Al-Beltagi M, Saeed NK, Mani PKC, Bediwy AS, Elbeltagi R (2025) Inflammatory bowel disease in paediatrics: navigating the old challenges and emerging frontiers. World J Gastroenterol 31:111934. https:\/\/doi.org\/10.3748\/wjg.v31.i35.111934","journal-title":"World J Gastroenterol"},{"key":"7443_CR4","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/apt.17217","volume":"56","author":"CJ Burgess","year":"2022","unstructured":"Burgess CJ, Jackson R, Chalmers I, Russell RK, Hansen R, Scott G, Henderson P, Wilson DC (2022) The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study. Aliment Pharmacol Ther 56:1453\u20131459. https:\/\/doi.org\/10.1111\/apt.17217","journal-title":"Aliment Pharmacol Ther"},{"key":"7443_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13318-025-00959-y","volume":"50","author":"RA Weersink","year":"2025","unstructured":"Weersink RA, Keizer RJ, Derijks LJJ (2025) Simulated dosing regimens of subcutaneous infliximab in adults and children with inflammatory bowel disease: exploring switch and initiation strategies. Eur J Drug Metab Pharmacokinet 50:419\u2013430. https:\/\/doi.org\/10.1007\/s13318-025-00959-y","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"8","key":"7443_CR6","doi-asserted-by":"publisher","first-page":"otag010","DOI":"10.1093\/crocol\/otag010","volume":"360","author":"L Vuitton","year":"2026","unstructured":"Vuitton L, Fumery M, Foulley L, Habauzit C, Benkhalifa S, Buisson A (2026) Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practice. Crohns Colitis 360(8):otag010. https:\/\/doi.org\/10.1093\/crocol\/otag010","journal-title":"Crohns Colitis"},{"key":"7443_CR7","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.dld.2023.12.013","volume":"56","author":"S Schreiber","year":"2024","unstructured":"Schreiber S, D\u2019Haens G, Cummings F, Irving PM, Ye BD, Ben-Horin S, Kim DH, Jeong AL, Reinisch W (2024) Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: post hoc longitudinal analysis of a randomized trial. Dig Liver Dis 56:1204\u20131212. https:\/\/doi.org\/10.1016\/j.dld.2023.12.013","journal-title":"Dig Liver Dis"},{"key":"7443_CR8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/ecco-jcc\/jjae059","volume":"18","author":"JD Chetwood","year":"2024","unstructured":"Chetwood JD, Tran Y, Subramanian S, Smith PJ, Iborra M, Buisson A, Paramsothy S, Leong RW (2024) Intravenous versus subcutaneous infliximab in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 18:1440\u20131449. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae059","journal-title":"J Crohns Colitis"},{"key":"7443_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MEG.0000000000002850","volume":"37","author":"AT Elford","year":"2025","unstructured":"Elford AT, Heldt R, Kamal S, Christensen B, Segal JP (2025) Systematic review with meta-analysis of the effectiveness of subcutaneous biologics versus intravenous biologics in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 37:47\u201354. https:\/\/doi.org\/10.1097\/MEG.0000000000002850","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"7443_CR10","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","volume":"21","author":"A Buisson","year":"2023","unstructured":"Buisson A, Nachury M, Reymond M, Yzet C, Wils P, Payen L, Laugie M, Manlay L, Mathieu N, Pereira B, Fumery M (2023) Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study. Clin Gastroenterol Hepatol 21:2338\u20132346. https:\/\/doi.org\/10.1016\/j.cgh.2022.08.011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7443_CR11","volume-title":"Cochrane handbook for systematic reviews of interventions, version 6.4","year":"2023","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2023) Cochrane handbook for systematic reviews of interventions, version 6.4. Cochrane"},{"key":"7443_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7443_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","volume":"58","author":"A Levine","year":"2014","unstructured":"Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L et al (2014) ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795\u2013806. https:\/\/doi.org\/10.1097\/MPG.0000000000000239","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7443_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"7443_CR15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res 27:1785\u20131805. https:\/\/doi.org\/10.1177\/0962280216669183","journal-title":"Stat Methods Med Res"},{"key":"7443_CR16","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18:2127\u20132133. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Evid Synth"},{"key":"7443_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"7443_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25. https:\/\/doi.org\/10.1186\/1471-2288-14-25","journal-title":"BMC Med Res Methodol"},{"key":"7443_CR19","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","volume":"67","author":"JJ Barendregt","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T (2013) Meta-analysis of prevalence. J Epidemiol Community Health 67:974\u2013978. https:\/\/doi.org\/10.1136\/jech-2013-203104","journal-title":"J Epidemiol Community Health"},{"key":"7443_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jrsm.1348","volume":"10","author":"G Schwarzer","year":"2019","unstructured":"Schwarzer G, Chemaitelly H, Abu-Raddad LJ, R\u00fccker G (2019) Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods 10:476\u2013483. https:\/\/doi.org\/10.1002\/jrsm.1348","journal-title":"Res Synth Methods"},{"key":"7443_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"7443_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2025.102680","volume":"49","author":"AS Duquerois","year":"2025","unstructured":"Duquerois AS, Martinez-Vinson C, Loppinet T, Restier L, Poinsot P, Portefaix A, Heissat S, Peretti N, Caron N, Duclaux-Loras R (2025) A series of pediatric patients with inflammatory bowel disease switching from intravenous to subcutaneous infliximab maintenance therapy. Clin Res Hepatol Gastroenterol 49:102680. https:\/\/doi.org\/10.1016\/j.clinre.2025.102680","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"7443_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/jpn3.70267","volume":"82","author":"JA Eldredge","year":"2026","unstructured":"Eldredge JA, Kaur R, Chua CW, Chidgey T, Tano M, Singh N, Barclay P, Magoffin A (2026) Subcutaneous infliximab use in children with inflammatory bowel disease in an Australian center. J Pediatr Gastroenterol Nutr 82:439\u2013446. https:\/\/doi.org\/10.1002\/jpn3.70267","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7443_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/ibd\/izaf335","volume":"32","author":"EH Boute","year":"2026","unstructured":"Boute EH, Gianolio L, Mahmmod S, Pochesci S, Armstrong K, Henderson P, Wilson DC, de Ridder L (2026) Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study. Inflamm Bowel Dis 32:1086\u20131096. https:\/\/doi.org\/10.1093\/ibd\/izaf335","journal-title":"Inflamm Bowel Dis"},{"key":"7443_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40348-026-00251-2","volume":"13","author":"N Ridder","year":"2026","unstructured":"Ridder N, Overberg J, Kalveram L, Pudasaini S, Ruppel C, Schumm L, Henning S, Bufler P (2026) Subcutaneous infliximab as a maintenance option in pediatric inflammatory bowel disease: a real-world cohort including younger and lower-weight children. Mol Cell Pediatr 13:38. https:\/\/doi.org\/10.1186\/s40348-026-00251-2","journal-title":"Mol Cell Pediatr"},{"key":"7443_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.70510","author":"PM Hughes","year":"2026","unstructured":"Hughes PM, Pittman N, Benkov K, Baez V, Festa J, Kennedy JM, Tung S, Dubinsky MC, Spencer EA (2026) Subcutaneous infliximab in pediatric inflammatory bowel disease: sustained remission, predictable pharmacokinetics, and real-world US implementation. J Pediatr Gastroenterol Nutr. https:\/\/doi.org\/10.1002\/jpn3.70510","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7443_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MPG.0000000000003838","volume":"77","author":"L Gianolio","year":"2023","unstructured":"Gianolio L, Armstrong K, Swann E, Shepherd R, Henderson P, Wilson DC, Russell RK (2023) Effectiveness of switching to subcutaneous infliximab in pediatric inflammatory bowel disease patients on intravenous maintenance therapy. J Pediatr Gastroenterol Nutr 77:235\u2013239. https:\/\/doi.org\/10.1097\/MPG.0000000000003838","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"Suppl 1","key":"7443_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf231.919","volume":"20","author":"JR Alberto","year":"2026","unstructured":"Alberto JR, De La Barreda HL, Marquez Rodriguez JA, Rodr\u00edguez D\u00edaz AE, Carrillo Palau M, Fuentes Ferrer ME, Hernandez Camba A (2026) Real-world experience of switching from intravenous to subcutaneous infliximab in pediatric inflammatory bowel disease patients: a multicenter retrospective cohort from the Canary Islands. Spain J Crohns Colitis 20(Suppl 1):i1909. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf231.919","journal-title":"Spain J Crohns Colitis"},{"key":"7443_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","volume":"16","author":"PJ Smith","year":"2022","unstructured":"Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S (2022) Efficacy and safety of elective switching from intravenous to subcutaneous infliximab (CT-P13): a multicentre cohort study. J Crohns Colitis 16:1436\u20131446. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac053","journal-title":"J Crohns Colitis"},{"key":"7443_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2023-001105","volume":"10","author":"I Carbery","year":"2023","unstructured":"Carbery I, Burdge G, Clark T, Broglio G, Greer D, Alakkari A, Selinger CP (2023) Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13). BMJ Open Gastroenterol 10:e001105. https:\/\/doi.org\/10.1136\/bmjgast-2023-001105","journal-title":"BMJ Open Gastroenterol"},{"key":"7443_CR31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1186\/s12913-022-08683-y","volume":"22","author":"HK Yoo","year":"2022","unstructured":"Yoo HK, Byun HG, Caprioli F, Fumery M, Peyrin-Biroulet L, Sreedhar S, Potter J, Jang M (2022) Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. BMC Health Serv Res 22:1319. https:\/\/doi.org\/10.1186\/s12913-022-08683-y","journal-title":"BMC Health Serv Res"},{"key":"7443_CR32","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/imj.16311","volume":"54","author":"P Hilley","year":"2024","unstructured":"Hilley P, Wong D, Ma R, Peterson A, De Cruz P (2024) Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare? Intern Med J 54:970\u2013979. https:\/\/doi.org\/10.1111\/imj.16311","journal-title":"Intern Med J"},{"key":"7443_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/PPA.S303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F, Allen JA (2021) Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence 15:811\u2013834. https:\/\/doi.org\/10.2147\/PPA.S303279","journal-title":"Patient Prefer Adherence"},{"key":"7443_CR34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/ibd\/izx080","volume":"24","author":"WJ Lee","year":"2018","unstructured":"Lee WJ, Lee TA, Calip GS, Suda KJ, Briars L, Schumock GT (2018) Risk of serious bacterial infection associated with tumor necrosis factor-alpha inhibitors in children and young adults with inflammatory bowel disease. Inflamm Bowel Dis 24:883\u2013891. https:\/\/doi.org\/10.1093\/ibd\/izx080","journal-title":"Inflamm Bowel Dis"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07443-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07443-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07443-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:37:15Z","timestamp":1791920235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07443-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7443"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07443-y","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"15 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review synthesized previously published, aggregate data and did not involve new research on human participants; institutional ethics approval was therefore not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; no individual participant data were used.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"786"}}